So-called secondary or follow-on patents target other aspects relating to semaglutide, e.g., peripheral or minor modifications, including new delivery devices, dosing regimens and formulations
doi: 10.1111/dom.12651 68 HeinlaKVasarESedmanTVolkeV
Food and Drug Administration for use in helping lose weight, GLP-1s saw a 300 percent increase in use between 2020 and 2022
This means they don't undergo the same rigorous testing as standard pharmaceuticals
2 DOSAGE AND ADMINISTRATION DOSAGE & ADMINISTRATION SECTION 3 DOSAGE FORMS AND STRENGTHS DOSAGE FORMS & STRENGTHS SECTION Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths
LBA 13 Chu, M